EASD 2025 15 - 19 September 2025

Effects of oral semaglutide on hospitalisation rates in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL trial results

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Diabetes

Congress oral presentation

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)